Research progress of Lipocalin-2 in obesity and related diseases

doi:10.3877/cma.j.issn.2095-9605.2023.01.010

Abstract

Abstract:

Adipokines play an important role in chronic metabolic and inflammatory diseases such as obesity, insulin resistance, and diabetes. Lipocalin-2 (LCN2), also known as neutrophil gelatinase-associated lipocalin, is a 25-kDa secretory glycoprotein that belongs to the lipocalin superfamily. LCN2 is widely expressed invarioustissues and cells, including adipocytes, hepatocytes, renal tubular cells, and osteoblasts. LCN2 is involved in maintaining iron homeostasis, promoting epithelial cell differentiation, and regulating immune responses. Revealing the relationship between LCN2 and obesity, diabetes and related diseasesmay provide new targets and ideas for the prevention and treatment of metabolic diseases.

Key words: Lipocalin-2, Adipokines, Obesity, Insulin resistance, Diabetes mellitus

Jinna Zhang, Jianing Gai, Ying Li. Research progress of Lipocalin-2 in obesity and related diseases[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(01): 50-54.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2023.01.010

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2023/V09/I01/50

Figures/Tables 1

References 32

[1]	Khanna D, Khanna S, Khanna P, et al.Obesity: A Chronic Low-Grade Inflammation and Its Markers [J]. Cureus, 2022, 14(2): e22711.
[2]	Hausmann J, Waechtershaeuser A, Behnken I, et al. The role of adipokines in the improvement of diabetic and cardiovascular risk factors within a 52-week weight-loss programme for obesity [J]. Obes Res Clin Pract, 2019, 13(5): 440-447.
[3]	Zorena K, Jachimowicz-Duda O, Ślęzak D, et al. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications [J]. Int J Mol Sci, 2020, 21(10): 3570.
[4]	Jaberi SA, Cohen A, D’Souza C, et al. Lipocalin-2: structure, function, distribution and role in metabolic disorders [J]. Biomed Pharmacother, 2021, 142: 112002.
[5]	Krizanac M, Mass Sanchez PB, Weiskirchen R, et al. A scoping review on lipocalin-2 and its role in non-alcoholic steatohepatitis and hepatocellular carcinoma [J].Int J Mol Sci, 2021, 22(6): 2865.
[6]	Yan QW, Yang Q, Mody N,et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance [J]. Diabetes. 2007, 56(10): 2533-40.
[7]	Zhang W, Chen S, Zhuang X. Research Progress on Lipocalin-2 in Diabetic Encephalopathy [J]. Neuroscience. 2023, 515: 74-82.
[8]	Zhang Y, Foncea R, Deis JA, et al. Lipocalin 2 expression and secretion is highly regulated by metabolic stress, cytokines, and nutrients in adipocytes [J]. PLoS One. 2014 May 12; 9(5): e96997.
[9]	Mosialou I, Shikhel S, Liu J-M, et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2 [J]. Nature, 2017, 543(7645): 385-390.
[10]	Currò D, Vergani E, Bruno C, et al. Plasmatic lipocalin‐2 levels in chronic low‐grade inflammation syndromes: comparison between metabolic syndrome, total and partial adult growth hormone deficiency [J]. BioFactors, 2020, 46(4): 629-636.
[11]	Petropoulou PI, Mosialou I, Shikhel S, et al. Lipocalin-2 is an anorexigenic signal in primates [J]. ELife, 2020, 9: e58949.
[12]	Mosialou I, Shikhel S, Luo N, et al. Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes [J]. J Exp Med, 2020, 217(10): e20191261.
[13]	Wang X, Li H, Li W,et al. The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy [J]. Cell Biol Toxicol. 2020 Oct; 36(5): 437-457.
[14]	Su X, Zhou P, Qi Y. Down-regulation of LCN2 attenuates retinal vascular dysfunction and caspase-1-mediated pyroptosis in diabetes mellitus [J]. Ann Transl Med, 2022, 10(12): 695.
[15]	Wang H, Lou H, Li Y, et al. Elevated vitreous lipocalin-2 levels of patients with proliferative diabetic retinopathy [J]. BMC Ophthalmol, 2020, 20(1): 260.
[16]	Parmar T, Parmar VM, Perusek L, et al. Lipocalin 2 plays an important role in regulating inflammation in retinal degeneration [J]. J Immunol, 2018, 200(9): 3128-3141.
[17]	Gan J, Zheng Y, Yu QL, et al. Serum Lipocalin-2 Levels Are Increased and Independently Associated With Early-Stage Renal Damage and Carotid Atherosclerotic Plaque in Patients With T2DM [J]. Front Endocrinol (Lausanne), 2022, 13: 855616.
[18]	Bhusal A, Lee WH, Suk K. Lipocalin-2 in Diabetic Complications of the Nervous System: Physiology, Pathology, and Beyond [J]. Front Physiol. 2021, 12: 638112.
[19]	Bhusal A, Lee WH, Suk K. Lipocalin-2 in Diabetic Complications of the Nervous System: Physiology, Pathology, and Beyond [J].Front Physiol, 2021, 12: 638112.
[20]	Bhusal A, Rahman MH, Lee WH,et al. Paradoxical role of lipocalin-2 in metabolic disorders and neurological complications [J]. Biochem Pharmacol, 2019, 169: 113626.
[21]	Naudé PJ, Nyakas C, Eiden LE, et al. Lipocalin 2: novel component of proinflammatory signaling in Alzheimer's disease [J]. FASEB J. 2012, 26(7): 2811-23.
[22]	Pinyopornpanish K, Phrommintikul A, Angkurawaranon C, et al. Circulating Lipocalin-2 level is positively associated with cognitive impairment in patients with metabolic syndrome [J]. Sci Rep, 2022, 12(1): 4635.
[23]	Rada P, González-Rodríguez á, García-Monzón C, et al. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? [J]. Cell Death Dis, 2020, 11(9): 802.
[24]	Lu J, Lin L, Ye C, et al. Serum NGAL Is Superior to Cystatin C in Predicting the Prognosis of Acute-on-Chronic Liver Failure [J]. Ann Hepatol, 2019, 18(1): 155-164.
[25]	Xu G, Wang YM, Ying MM, et al. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis [J]. Clin Mol Hepatol, 2021, 27(2): 329-345.
[26]	Asimakopoulou A, Fülöp A,Borkham-KamphorstE, et al. Altered mitochondrial and peroxisomal integrity in lipocalin-2-deficient mice with hepatic steatosis [J]. Biochim Biophys Acta Mol Basis Dis, 2017, 1863(9): 2093-2110.
[27]	Chen J, Lei S, Huang Y, et al. The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery [J]. Lipids Health Dis. 2022, 21(1): 10.
[28]	Shibata K, Sato K, Shirai R, et al. Lipocalin-2 exerts pro-atherosclerotic effects as evidenced by in vitro and in vivo experiments [J]. Heart Vessels. 2020, 35(7): 1012-1024.
[29]	Francisco V, Pino J, Gonzalez-Gay MA, et al. Adipokines and inflammation: is it a question of weight? [J]. Br J Pharmacol. 2018, 175(10): 1569-1579.
[30]	Cheng F, Ng NYH, Tam CHT, et al. Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS [J]. Endocr Connect, 2021, 10(10): 1243-1252.
[31]	Cakal E, Ozkaya M, Engin-Ustun Y, et al. Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome [J]. J Endocrinol Invest, 2011, 34(2): 97-100.
[32]	Kruszewska J, Laudy-Wiaderny H, Kunicki M. Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients-The Debate Is Still Open [J]. Int J Environ Res Public Health, 2022, 19(4): 2099.

Please choose a citation manager

Content to export